Ultime notizie per Redhill Biopharma (NASDAQ:RDHL) Azioni

Redhill Biopharma

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma Ltd

ON24 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTF#NYSE">ONTF</a>), a leading intelligent engagement platform for B2B marketing, today announced that its Board of Directors has authorized a share repurchase where ON24 may purchase up to $50 million of its common stock.

News

Buybacks

ONTF

ON24 Authorizes $50M Share Repurchase Program

Gold Resource (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GORO#AMEX">GORO</a>) reported quarterly losses of $(0.07) per share. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $12.35 million in sales this quarter. This is a 33.94 percent decrease over sales of $18.70 million the same period last year.

Earnings

GORO

Gold Resource Q1 EPS $(0.07) Down From $(0.06) YoY, Sales $12.35M Down From $18.70M YoY

CDIOW

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 15 years by 2.1% on an annualized basis producing an average annual return of 13.7%. Currently, Graphic Packaging Holding has a market capitalization of $6.96 billion. 
Buying $100 In GPK: If an investor had bought $100 of GPK stock 15 years ago, it would be worth $660.74 today based on a price of $23.06 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747093515_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Graphic Packaging Holding 15 Years Ago Would Be Worth This Much Today

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) has outperformed the market over the past 15 years by 4.93% on an annualized basis producing an average annual return of 16.53%. Currently, McKesson has a market capitalization of $86.16 billion. 
Buying $100 In MCK: If an investor had bought $100 of MCK stock 15 years ago, it would be worth $1,002.22 today based on a price of $687.52 for MCK at the time of writing.
<h3>McKesson's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747092613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In McKesson 15 Years Ago Would Be Worth Today

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 15 years by 1.49% on an annualized basis producing an average annual return of 13.09%. Currently, Union Pacific has a market capitalization of $137.94 billion. 
Buying $1000 In UNP: If an investor had bought $1000 of UNP stock 15 years ago, it would be worth $6,214.54 today based on a price of $230.87 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747091712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Union Pacific 15 Years Ago Would Be Worth Today

Warren Buffett has worn the title of "richest man in the world." He's built one of the most powerful holding companies in history. And he's spent decades casually throwing around billion-dollar deals like most people swipe for lattes.
Yet, in his own words, he doesn't need the money.
In 2021, in a statement titled "Comments by Warren E. Buffett in Conjunction with His Annual Contribution of Berkshire Hathaway Shares to Five Foundations," Buffett wrote:
"Over many decades I have accumulated an almost incomprehensible sum simply by doing what I love to do… Society has a use for my money; I don't."
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<a href="https://www.forbes.com/profile/warren-buffett/">According to Forbes</a>, he's donated roughly $62 billion since 2006—part of his long-standing pledge to give away more than 99% of his wealth. Unlike many billionaires who cling to their fortunes or spend it on jets, islands, or ego projects, Buffett's message has been the same: he doesn't need it, he doesn't want it, and he's more than happy to let society put it to better use.
Buffett has made it clear—again and again—that money holds no personal appeal. In a <a href="https://www.bloomberg.com/news/videos/2016-11-02/warren-buffett-money-has-no-utility-to-me-time-does">2016 interview on "The David Rubenstein Show"</a>, he said, "Money in terms of making trips or owning more houses or having a boat or something — it has no utility to me whatsoever."&nbsp;
This is a man who could buy a skyscraper every time he gets bored—but he lives in the same house he bought in <a href="https://www.benzinga.com/personal-finance/25/02/43612207/warren-buffett-has-lived-in-his-31500-home-for-67-years-and-calls-it-one-of-his-best-investments-but-warned-a-house-can-be-a-nightmare">1958 for $31,500</a> and says no other home would make him happier. He drives a 2014 Cadillac with hail damage. He drinks Cherry Coke like it's water.&nbsp;
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
And while the average millionaire might spend weeks negotiating over a single property, <a href="https://www.benzinga.com/personal-finance/25/03/44464242/warren-buffett-said-i-love-your-business-i-love-you-ill-give-you-4-billion-but-refused-to-cross-an-ocean-to-see-a-business-before-buying-it">Buffett once bought a $4 billion company</a>—Israeli metal giant Iscar—without ever stepping foot inside. Another time, he acquired the <a href="https://www.benzinga.com/markets/25/03/44067982/heres-how-warren-buffett-made-billions-from-an-industry-he-didnt-understand">RV company Forest River after a 20-minute chat</a> with the founder.
Although in 2021—when he made the statement about accumulating "an almost incomprehensible sum"—his plan was to give his fortune to five foundations, that's since changed.&nbsp;
In 2025, Buffett revised his estate plan: the remaining $130 billion will instead be transferred to a charitable trust overseen by his three children—Susan, Howard, and Peter. All decisions about how the money is distributed must be made unanimously, a structure Buffett believes will lead to careful, collaborative giving.
Buffett calls his brand of giving "painless," because he's not giving up anything he personally needs. <a href="https://www.benzinga.com/personal-finance/25/05/45240439/ive-made-no-sacrifice-warren-buffett-has-given-away-60-billion-but-says-giving-time-is-more-admirable-ive-done-little-of-that">"I've made no sacrifice,"</a> he said. And he means it. His joy doesn't come from spending—it comes from doing what he loves: investing, building, buying, and reading company reports for fun.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Warren Buffett Says He Made An 'Incomprehensible Sum' Doing What He Loves — But The Money Means Little: 'Society Has A Use For My Money; I Don't'

Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has outperformed the market over the past 5 years by 13.02% on an annualized basis producing an average annual return of 28.31%. Currently, Natera has a market capitalization of $21.48 billion. 
Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $348.60 today based on a price of $157.29 for NTRA at the time of writing.
<h3>Natera's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747090814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTRA

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today

Media network CBS has dominated the prime time ratings for more than a decade and helped boost the financials for Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) and subscribers for the company's<a href="https://www.benzinga.com/topic/streaming"> Paramount+ streaming platform.</a>
With concerns over a pending merger and pressure from President Donald Trump, could TV success offset a declining stock price?
What Happened: Paramount Global has a pending merger with Skydance Media. The merger has faced regulatory pressure and a<a href="https://www.benzinga.com/25/04/44793888/trump-attacks-60-minutes-for-unlawful-and-illegal-behavior-could-president-derail-merger"> fight from Trump</a> to take away CBS's FCC broadcast license over past "60 Minutes" episodes could keep the stock from breaking out.
Paramount's CBS Television segment could be a bright spot and shows no signs of slowing down.
As reported by <a href="https://variety.com/2025/biz/news/cbs-upfront-victory-lap-matlock-cheeks-reisenbach-1236393491/">Variety</a>, CBS chose to release its 2025-26 season schedule ahead of media company upfronts, which is when they show off their lineups and new content to advertisers.
Likely helping CBS's decision were several victory laps taken by George Cheeks and Amy Reisenbach over the network's streak of 17 consecutive years as the most-watched network. CBS also has eight of the top 10 most-watched series on television and 16 of the top 25 based on Nielsen data.
CBS has newer hit shows that include "Tracker" and "Matlock." These hit shows and originals have provided a boost to Paramount+, where CBS programs get around half of the total viewing on the platform, according to the report.
"The bottom line here is, our broadcast hits are becoming instant streaming hits," Cheeks said.
Producer Taylor Sheridan has spawned several hits for CBS, including the "Yellowstone" franchise and has more series in the works for CBS, adding more excitement to the company's lineup of returning programs.
"We made some very strategic scheduling moves that will reinforce the schedule that clinched us our 17 seasons at the most-watched network. This is a lineup that's going to be cohesive and has flow with compatible programming each night and throughout the week, and provides strong launch pads for all of our new series," Reisenbach added.
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/05/45201601/trump-wants-movies-made-in-america-again-heres-what-tariffs-on-films-could-mean-for-disney-netflix-stock">Trump Wants &#8216;Movies Made In America Again&#8217;: Here&#8217;s What Tariffs On Films Could Mean For Disney, Netflix Stock</a>
Why It's Important: The success of the television segment and a look ahead at what's to come comes as Trump has put pressure on CBS and "60 Minutes," an item that could delay or end the company's merger hopes with Skydance Media.
"This is a disruptive and challenging time for our industry," Cheeks said at the recent event, choosing not to answer questions outside of CBS programming.
"We have to focus on what we control, which is building an amazing schedule."
With the merger in limbo, shareholders face the decision of sticking things out for the combined company or the realization that a merger not going through could send shares lower and force the company to show valuation from the CBS assets on its own.
Paramount <a href="https://www.benzinga.com/general/entertainment/25/05/45358172/paramounts-super-bowl-boost-and-studio-strength-help-offset-streaming-miss-analyst">reported first-quarter</a> revenue of $7.19 billion, beating Street consensus estimates. The company's television segment had revenue of $4.54 billion, beating estimates, while direct-to-consumer revenue of $2.04 billion came in shy of estimates from analysts.
The company's guidance suggests streaming could face tough comps going forward, putting more pressure on the television segment to continue to perform well and be the top-ranked network for the 19th straight year.
PARA Price Action: Paramount stock closed at $11.95 on Monday versus a 52-week trading range of $9.54 to $13.40. Paramount stock is up 13% year-to-date, with shares down 8% over the last year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/24/09/40754610/paramount-to-be-controlled-by-worlds-sixth-richest-man-larry-ellison-how-helping-his-son-la">Paramount To Be Controlled By World&#8217;s Sixth-Richest Man Larry Ellison: How Helping His Son Landed A Media Stake</a></li>
</ul>
Photo: Fotos593 via Shutterstock

Entertainment

Politics

Media

PARA

PARAA

CBS Highlights TV Dominance, 17-Year Streak On Top: Can Success Help Offset Trump, Merger Concerns?

Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) has outperformed the market over the past 5 years by 6.69% on an annualized basis producing an average annual return of 21.98%. Currently, Primerica has a market capitalization of $9.04 billion. 
Buying $1000 In PRI: If an investor had bought $1000 of PRI stock 5 years ago, it would be worth $2,700.76 today based on a price of $273.29 for PRI at the time of writing.
<h3>Primerica's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747089912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 48.15 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $6.44 million which missed the analyst consensus estimate of $7.42 million by 13.21 percent. This is a 1.24K percent increase over sales of $481.00 thousand the same period last year.

Earnings Misses

SGMO

Sangamo Therapeutics Q1 EPS $(0.14) Misses $(0.13) Estimate, Sales $6.44M Miss $7.42M Estimate

Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $0.75 per share, will become exercisable six months from the date of issuance and will expire six years from the date of issuance. All of the securities in the offering are to be sold by Sangamo. The offering is expected to close on or about May 14, 2025, subject to the satisfaction of customary closing conditions.
The gross proceeds to Sangamo from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $23.0 million. Sangamo intends to use the net proceeds from the offering for working capital and general corporate purposes.
Cantor is acting as sole book-running manager for the offering.

Offerings

Sangamo Therapeutics Prices $23M Underwritten Offering Of 12.235M Shares Of Common Stock And Pre-Funded Warrants At $0.50 And $0.49 Respectively, Including Accompanying Warrants Exercisable At $0.75

Tandy Leather Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLF#NASDAQ">TLF</a>) reported quarterly earnings of $0.05 per share. This is a 16.67 percent decrease over earnings of $0.06 per share from the same period last year. The company reported $19.04 million in sales this quarter. This is a 1.24 percent decrease over sales of $19.27 million the same period last year.

UPDATE: Tandy Leather Factory Q1 Adj. EPS $0.05 Down From $0.06 YoY, Sales $19.04M Down From $19.27M YoY

Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) reported quarterly earnings of $2.80 per share which beat the analyst consensus estimate of $1.92 by 45.83 percent. This is a 42.86 percent decrease over earnings of $4.90 per share from the same period last year. The company reported $414.00 million in sales this quarter. This is a 3.24 percent increase over sales of $401.00 million the same period last year.

Earnings Beats

Pampa Energia Q1 EPADS $2.80 Beats $1.92 Estimate, Sales $414.00M Up From $401.00M YoY

Infinity Natural (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INR#NYSE">INR</a>) reported quarterly losses of $(2.27) per share. The company reported $85.17 million in sales this quarter. This is a 69.57 percent increase over sales of $50.23 million the same period last year.

Morgan Stanley Market Vectors Rupee/USD ETN

Infinity Natural Q1 EPS $(2.27), Sales $85.17M Up From $50.23M YoY

BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) reported quarterly losses of $(0.06) per share. This is a 20 percent decrease over losses of $(0.05) per share from the same period last year.

BYSI

UPDATE: BeyondSpring Q1 EPS $(0.06) Down From $(0.05) YoY

Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) has outperformed the market over the past 20 years by 4.32% on an annualized basis producing an average annual return of 12.57%. Currently, Applied Mat has a market capitalization of $136.70 billion. 
Buying $100 In AMAT: If an investor had bought $100 of AMAT stock 20 years ago, it would be worth $1,053.89 today based on a price of $168.20 for AMAT at the time of writing.
<h3>Applied Mat's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747088112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMAT

$100 Invested In Applied Mat 20 Years Ago Would Be Worth This Much Today

Hertz Global Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) reported financial results for the first quarter after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/n45362896/hertz-reports-significant-progress-towards-key-milestones-for-first-quarter-2025">of the report</a>.
<ul class="wp-block-list">
<li>Q1 Revenue: $1.81 billion, versus <a href="http://benzinga.com/quote/htz/earnings">estimates</a> of $2 billion</li>
</ul>
<ul class="wp-block-list">
<li>Q1 Adjusted Loss: $1.12, versus estimates of 97 cents</li>
</ul>
Total revenue declined 13% on a year-over-year basis, primarily driven by reduced fleet capacity, which was down 8% year-over-year. The company said its fleet rotation is delivering results, with vehicle depreciation down 45% year-over-year. 
Hertz said it&#8217;s targeting less than $300 of depreciation per unit in the second quarter, with model year 2025 vehicles already achieving this target. The company noted that more than 70% of its core U.S. rental fleet is 12 months old or newer. 
Hertz ended the quarter with $1.2 billion of corporate liquidity and said it remains on track to achieve positive adjusted corporate EBITDA by the third quarter of 2025. 
&#8220;Given macro demand uncertainties, it is intentionally running a tighter fleet year-over-year while capitalizing on the strong residual value environment to accelerate the rotation of its remaining older vehicles,&#8221; the company said in the earnings release.
&#8220;Looking forward, the Company sees both macroeconomic uncertainty and opportunity. The Company has recently seen demand moderate for corporate, government and U.S. inbound segments while forward bookings for Hertz leisure are up year-over-year. The Company intends to remain prudent in its fleet management, entering the summer with a relatively tight fleet, and thereby leveraging rising residual values.&#8221;
Hertz executives will further discuss the quarter on a conference call with investors and analysts at 9 a.m. ET Tuesday morning.
HTZ Price Action:<a href="http://benzinga.com/quote/htz"> Hertz shares</a> were down 3.60% after hours, trading at $6.69 at the time of publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Hertz shares surged last month after Bill Ackman's&nbsp;Pershing Square Capital Management reported a sizable stake in the company. Despite Monday&#8217;s after-hours decline, the stock is still up approximately 89% year-to-date.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45362510/microvision-stock-tumbles-on-q1-earnings-miss-company-highlights-industrial-revenue-opportunities-targets-defense-tech-military-expansion">MicroVision Stock Tumbles On Q1 Earnings Miss, Company Highlights Industrial Revenue Opportunities, Targets Defense Tech, Military Expansion</a></li>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45361467/archer-aviation-reports-smaller-than-expected-loss-in-q1-company-says-uae-launch-remains-on-track-for-2025-shares-surge">Archer Aviation Reports Smaller-Than-Expected Loss In Q1, Company Says UAE Launch Remains &#8216;On Track&#8217; For 2025, Shares Surge</a></li>
</ul>
Photo: ricochet64/Shutterstock.

Movers

Hertz Stock Hits The Brakes Following Q1 Earnings Results: Key Details From The Report

ACHR

Archer Aviation Files For Offering Of Up To $19.25M Of Shares Of Class A Common Stock

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer's Darolutamide, To Overcome Androgen Resistance

Press Releases

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Small Cap

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RDHL

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

Biofrontera

CNS Pharma

Enveric Biosciences

Evoke Pharma

Eyenovia

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Impact BioMedical

Jaguar Health

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

cbdMD

Screenshot 2025-02-25 at 7.29.32 PM

Biotech

General

RedHill Licenses RHB-102 Worldwide Excluding North America To Hyloris For Up To $60M In Potential Milestone Payments Plus Royalties

Screenshot 2025-02-04 at 6.43.58 PM

BAYRY

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill&#39;s Opaganib And Bayer&#39;s Darolutamide, To Overcome Androgen Resistance

Comments

Redhill Biopharma

Notizie

Ultime notizie per Redhill Biopharma (NASDAQ:RDHL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO